Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis
Aortic valve stenosis (AVS) is the most prevalent disease in the Western World with exponentially increased incidence with age. If left untreated, the yearly mortality rates increase up to 25%. Currently, no effective pharmacological interventions have been established to treat or prevent AVS. The o...
Main Authors: | Johan G. Schnitzler, Lubna Ali, Anouk G. Groenen, Yannick Kaiser, Jeffrey Kroon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/9/12/760 |
Similar Items
-
Editor’s Pick: Lipoprotein(a) and Calcific Aortic Valve Stenosis
by: Constantine E. Kosmas, et al.
Published: (2019-10-01) -
Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis
by: Maristella Donato, et al.
Published: (2020-11-01) -
Upregulated Autophagy in Calcific Aortic Valve Stenosis Confers Protection of Valvular Interstitial Cells
by: Miguel Carracedo, et al.
Published: (2019-03-01) -
Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis
by: Raphaëlle Bourgeois, et al.
Published: (2021-07-01) -
Label-Free Multiphoton Microscopy for the Detection and Monitoring of Calcific Aortic Valve Disease
by: Ishita Tandon, et al.
Published: (2021-06-01)